- Home
- GIGM vs GDTC Comparison
GIGM vs GDTC Comparison
Compare GIGM & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GIGM | GDTC |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | Taiwan | Singapore |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8M | 15.5M |
| IPO Year | 2002 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GIGM | GDTC |
|---|---|---|
| Price | $1.57 | $1.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.9K | ★ 455.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $5.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.38 | $0.73 |
| 52 Week High | $1.89 | $3.68 |
Technical Indicators
Market Signals| Indicator | GIGM | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 54.80 | 47.58 |
| Support Level | $1.42 | $0.87 |
| Resistance Level | $1.59 | $2.25 |
| Average True Range (ATR) | 0.04 | 0.11 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 66.67 | 45.25 |
Price Performance
Historical ComparisonAbout GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.